With Sanofi's mighty Dupixent chasing behind, Takeda's Eohilia suffers FDA rejection after mysterious delay

Another piece of bad news has hit Takeda’s Wave 1 pipeline, dealing a blow to the Japanese pharma’s plan to deliver a boost to near-term sales.

After missing a decision deadline in April, the FDA has rejected Takeda’s Eohilia, an oral suspension formulation of the corticosteroid budesonide, the company said Tuesday.